Journal of the American Academy of Dermatology
Volume 61, Issue 6 , Pages 961-970.e11 , December 2009

Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participants

  • Mitchell F. Brin, MD

      Affiliations

    • Allergan, Irvine, California
    • University of California, Irvine, California
    • Corresponding Author InformationReprint requests: Mitchell F. Brin, MD, Allergan, 2525 Dupont Dr, T1-1B, Irvine, CA 92623-9534.
    • ,
  • Terry I. Boodhoo, MS

      Affiliations

    • Allergan, Irvine, California
    • ,
  • Janice M. Pogoda, PhD

      Affiliations

    • University of Southern California, Los Angeles, California
    • ,
  • Lynn M. James, MPH

      Affiliations

    • Allergan, Irvine, California
    • ,
  • George Demos, MD

      Affiliations

    • Allergan, Irvine, California
    • ,
  • Yasunori Terashima, MD, PhD

      Affiliations

    • GlaxoSmithKline K.K., Shibuya-ku, Tokyo
    • ,
  • Juanhong Gu, MS

      Affiliations

    • GlaxoSmithKline China Investment Co Ltd, Shanghai, China
    • ,
  • Nina Eadie, MBA

      Affiliations

    • independent contractor, Corvallis, Montana
    • ,
  • Beta L. Bowen, MS

      Affiliations

    • Allergan, Irvine, California

,Accepted 8 June 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The writing of the manuscript and associated statistical analyses were funded by Allergan. All studies reported herein were funded by the sponsoring pharmaceutical companies: Allergan, GlaxoSmithKline Japan, and GlaxoSmithKline China.

 Disclosure: Dr Brin, Mr Boodhoo, Ms James, Dr Demos, Dr Terashima, Ms Gu, and Ms Bowen are employed by the pharmaceutical companies and receive direct salary compensation. Dr Brin, Ms Eadie, Ms Bowen, Mr Boodhoo, Dr Demos, and Ms James also hold an equity interest in the companies in the form of stock, stock options, or both. Dr Pogoda and Ms Eadie have consulting contracts with Allergan. None of the authors have any commercial associations with any company that makes a competing product. No ghost writers or other third parties were involved in the preparation of the manuscript.

PII: S0190-9622(09)00725-7

doi: 10.1016/j.jaad.2009.06.040

Journal of the American Academy of Dermatology
Volume 61, Issue 6 , Pages 961-970.e11 , December 2009

Article Tools

* Image Usage & Resolution